Dynavax Technologies Corporation News Releases http://investors.dynavax.com/ Dynavax Technologies Corporation News Releases en Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business http://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-strategic-restructuring-focus-its-vaccine Company will explore strategic alternatives for its immuno-oncology programs Company will align its resources to focus on HEPLISAV-B commercialization Eddie Gray , CEO, to retire BERKELEY, Calif. , May 23, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a Thu, 23 May 2019 16:45:00 -0400 Dynavax Technologies Corporation News Releases 17311 Dynavax Announces First Quarter 2019 Financial Results http://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-first-quarter-2019-financial-results First quarter 2019 HEPLISAV-B® net product revenue of $5.6 million Conference call to be held today at 4:30 p.m. ET / 1:30 p.m. PT BERKELEY, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on Wed, 08 May 2019 16:05:00 -0400 Dynavax Technologies Corporation News Releases 17296 Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in Adults With End-Stage Renal Disease http://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-first-patient-enrolled-study-heplisav-br Trial to evaluate immunogenicity and safety of Hepatitis B vaccine, HEPLISAV-B, in patients with end-stage renal disease who are initiating or undergoing dialysis BERKELEY, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated Thu, 02 May 2019 17:00:00 -0400 Dynavax Technologies Corporation News Releases 17286 Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8 http://investors.dynavax.com/news-releases/news-release-details/dynavax-technologies-report-first-quarter-2019-financial-results BERKELEY, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its first quarter 2019 financial results on Thu, 25 Apr 2019 16:05:00 -0400 Dynavax Technologies Corporation News Releases 17281 Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019 http://investors.dynavax.com/news-releases/news-release-details/dynavax-present-data-toll-receptor-9-agonist-sd-101-asco-annual BERKELEY, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present data from a Phase 1b/2 Thu, 18 Apr 2019 16:05:00 -0400 Dynavax Technologies Corporation News Releases 17261 Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting http://investors.dynavax.com/news-releases/news-release-details/dynavax-presents-phase-1b-data-inhaled-dv281-tlr9-agonist-2019 Using an investigational safety treatment regimen, inhaled DV281 in combination with systemic nivolumab was well tolerated in a population of heavily pre-treated NSCLC patients Target engagement was observed at all dose levels Evidence of anti-tumor effects was seen at all dose levels BERKELEY, Tue, 02 Apr 2019 13:00:00 -0400 Dynavax Technologies Corporation News Releases 17246 Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models http://investors.dynavax.com/news-releases/news-release-details/dynavaxs-sd-101-and-4scs-domatinostat-demonstrate-synergy-and BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany , April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) and 4SC AG (FSE Prime Standard: VSC) today announced the combination of 4SC’s orally available class I selective HDAC inhibitor domatinostat (4SC-202) with Mon, 01 Apr 2019 13:00:00 -0400 Dynavax Technologies Corporation News Releases 17236 Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults http://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-european-medicines-agency-accepts-marketing BERKELEY, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has Thu, 28 Mar 2019 16:05:00 -0400 Dynavax Technologies Corporation News Releases 17231 Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019 http://investors.dynavax.com/news-releases/news-release-details/dynavax-present-inhaled-tlr9-agonist-dv281-aacr-annual-meeting BERKELEY, Calif. , March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present safety and biomarker data for Wed, 20 Mar 2019 16:20:00 -0400 Dynavax Technologies Corporation News Releases 17226 Dynavax Exercises Option for $75 Million in Non-Dilutive Debt http://investors.dynavax.com/news-releases/news-release-details/dynavax-exercises-option-75-million-non-dilutive-debt Proceeds to fund HEPLISAV-B® commercialization activities and completion of ongoing immuno-oncology studies BERKELEY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has exercised its option to draw down $75 million of non-dilutive Mon, 18 Mar 2019 16:05:00 -0400 Dynavax Technologies Corporation News Releases 17216